ArticleBMC public health2025
Awareness, acceptability, and willingness to pay for the R21/Matrix-M malaria vaccine: a cross-sectional study among pregnant women and nursing mothers in Enugu State, Nigeria.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe R21/Matrix-M vaccine has significantly reduced incident malaria in children aged 3–36 months, but awareness, acceptance, and affordability of the vaccine are key to its successful rollout. The objective of this study was to assess the awareness, acceptability, and willingness to pay (WTP) for the R21/Matrix-M malaria vaccine among pregnant women and nursing mothers in Enugu State, Nigeria.
methodsA descriptive cross-sectional study was carried out in the selected locations via a 30-item, 4-section questionnaire. Descriptive statistics (frequency, percentage, mean and median) and inferential statistics (chi-square test and binary logistic regression) were used to analyze the data, with the significance level set at p ≤ 0.05.
resultsOf the 310 participants, most were aged 22–33 years, 232 (75.0%) and had at least one child aged 3 years and younger, 180 (58.1%). Additionally, the majority were not aware of the R21/Matrix-M malaria vaccine, 262 (84.5%); agreed to vaccinate their child, 292 (94.2%); and declared a WTP, 247 (79.7%). The mean and median maximum WTP values were US $0.82 ± 1.41 (₦639.27 ± 1097) and US $0.38 (₦300) [Official USD ($) rate; (1 USD = ₦780) as of June–July 2023], respectively. Age (p = 0.005) and health insurance (p = 0.021) were significantly associated with the respondents’ WTP. Health insurance (OR: 0.417, 95% CI: 0.19–0.92) also predicted a lower WTP.
conclusionDespite limited awareness of the R21/Matrix-M malaria vaccine, participants demonstrated high acceptance and a strong WTP, suggesting that increased awareness could lead to high vaccine coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.